



## NEWS RELEASE

Media Relations Contacts:

Len Hall

Allen & Caron, Inc.

(949) 474-4300

[len@allencaron.com](mailto:len@allencaron.com)

Investor Relations Contact:

Matt Clawson or Dan Matsui

Allen & Caron, Inc.

(949) 474-4300

[matt@allencaron.com](mailto:matt@allencaron.com)

### **BIOLIFE SOLUTIONS NAMES MEDICAL TECHNOLOGY EXECUTIVE RAYMOND W. COHEN TO BOARD OF DIRECTORS**

OWEGO, NY (May 17, 2006) BioLife Solutions, Inc. (OTC BB: BLFS), a leading manufacturer and marketer of cryopreservation solutions for the preservation of cells and tissues at low temperatures, announced today that veteran medical technology executive Raymond W. Cohen has been appointed to its Board of Directors, effective immediately. Cohen fills a vacancy on the Board, increasing the size of the Board to five Directors.

Cohen, 47, is an accredited director and currently serves as Chief Executive Officer of Laguna Hills, CA-based Symphony Medical, Inc., a venture capital backed privately-held developer of biologic solutions for the treatment of cardiac conduction abnormalities. Cohen also serves as the Chairman of Board of Directors of Bothell, WA-based Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products formed by the September merger of Quinton Cardiology Systems, Inc., and Cardiac Science, Inc., where Cohen served as Chief Executive Officer for nine years. Cohen also serves as a member of the Board of Directors of Synchroness, Inc., a privately-held contract engineering and product development firm based in Westminster, CO. He is a member of the Advisory Board for the College of Osteopathic Medicine, Western University of Health Sciences in Pomona, CA.

BioLife Solutions Chief Executive Officer John Baust said, "We're confident that we will benefit greatly from Ray's 25 years of leadership and entrepreneurial experience in healthcare. He has expertise in areas that are critical to the growth of BioLife including strategic alliances, new product development capital raising and regulatory compliance. We look forward to Ray's contributions as BioLife executes on our plan to expand our business in the growing field of human cell and tissue engineering."

#### **About BioLife Solutions**

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) preservation media are marketed directly to



companies, laboratories, and academic institutions engaged in research and commercial clinical applications. BioLife's line of serum-free and protein-free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function. For more information please visit BioLife Solutions' website at <http://www.biolifesolutions.com>.

*This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.*

###